• Jiaqi Li, Haojia Wang, Rui Shi, Xiaomeng Zhang, Yifan Lin, Huijuan Cao, and Jiarui Wu.
• School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, China.
• Medicine (Baltimore). 2024 Jan 19; 103 (3): e37025e37025.

ObjectiveTo systemically evaluate the efficacy and safety of diterpene ginkgolides meglumine injection (DGMI) on cerebral infarction (CI).MethodsComprehensively collect randomized controlled trials of DGMI in the treatment of CI in 7 databases including Embase, PubMed, the Cochrane Library, the China National Knowledge Infrastructure Database, the WanFang Database, the China Science and Technology Journal Database, and the China Biology Medicinedisc as of January 2023. The studies were screened according to the inclusion and exclusion criteria and evaluated according to the criteria recommended by the Cochrane Handbook, then RevMan 5.3, Stata 12.0 software were used for Meta-analysis.ResultsA total of 22 randomized controlled trials with 2194 patients were included. Meta analysis showed that: the total effective rate of treatment (relative risk = 1.29, 95% confidence interval (1.21, 1.38), P < .001), National Institute of Health stroke scale score, Barthel index and Modified Rankin Scale were better in DGMI group than in Conventional Western Medicine Treatment group. The included studies reported 42 adverse events, 25 of which belonged to DGMI groups.ConclusionAvailable evidence suggested that DGMI can significantly improve the clinical efficiency in the treatment of CI. DGMI is an ideal treatment for CI, which has high clinical application value.Copyright © 2024 the Author(s). Published by Wolters Kluwer Health, Inc.

25 keywords...

hide…